General Information

• Discontinued in US in 2002

---

Indications

• Heparin-Induced Thrombocytopenia (HIT) (see Heparin-Induced Thrombocytopenia, [[Heparin-Induced Thrombocytopenia]])
  • One of the recommended agents, per Chest 2012 guidelines [MEDLINE]: however, it is not FDA approved for HIT

---

Pharmacology

• Factor Xa Inhibitor (see Factor Xa Inhibitors, [[Factor Xa Inhibitors]])
• Half-Life: 25 hrs
• Metabolism: renal

---

Administration

• IV
• SQ

---

Adverse Effects

Hemorrhagic Adverse Effects

• Diffuse Alveolar Hemorrhage (DAH) (see Diffuse Alveolar Hemorrhage, [[Diffuse Alveolar Hemorrhage]]
• Gastrointestinal Hemorrhage (see Gastrointestinal Hemorrhage, [[Gastrointestinal Hemorrhage]])
• Intracerebral Hemorrhage (Hemorrhagic Cerebrovascular Accident) (see Intracerebral Hemorrhage, [[Intracerebral Hemorrhage]])
• Intracranial Epidural Hematoma (see Intracranial Epidural Hematoma, [[Intracranial Epidural Hematoma]])
• Spinal Epidural Hematoma (see Spinal Epidural Hematoma, [[Spinal Epidural Hematoma]])
• Subarachnoid Hemorrhage (SAH) (see Subarachnoid Hemorrhage, [[Subarachnoid Hemorrhage]])
• Subdural Hematoma (SDH) (see Subdural Hematoma, [[Subdural Hematoma]])

Other Adverse Effects

• xxx
• xxx

---

References

• xxxx